Harman International Industries, Inc.

Janssen Biotech, Inc.

Other

Crowdstrike, Inc.

Eli Lilly and Company

USA As Represented by Secretary of the Navy

Sutro Biopharma, Inc.

Georgia Tech Research Corporation

Ansys, Inc.

Synopsys, Inc.

Mattel, Inc.

The Directv Group, Inc.

Gilead Sciences, Inc.

Maxtor Corporation

Samsara Networks Inc.

John Lee

Timothy J Shuttleworth

Richard Allen Kreifeldt

William A Plunkett

Bruce Vander Werf

Andrew Stevenson

Qi-Ying Hu

Fuxin Shi

Lili Guo

Altan Odabasi

Murat Becer

Aaron Sato

Sanjaya Singh

Richard J Lee

Rajkumar Ganesan

Michael Naso

Ryan Stafford

Jorge Alsina-Fernandez

Hongchang Qu

Alice Yam

Gilbert F Lee

Arunachalam Muthu

Kush Santosh

Fakhruddin Hatim Chopdawala

Jill Marie Mooney

Bruce T Hartmann

Akshat Keshan

Jaron Michael Bradley

Howard Scott Zollinger

Cory-Khoi Quang Nguyen

John Gajewski

Samantha Grace Lyons Keyser

Brody Nisbet

Peter Randazzo

Nicholas A Illobre

Dionisio Espinal

Gerald Matthew Bavaro

David Michael Yonchak

Kelly Renee Leger

Jinquan Luo

Ellen Chi

Scott Johnson

Chichi Huang

Wilson Edwards

Junhao Yang

Sathyadevi Venkataramani

Theresa Marie McDevitt

Fang Yi

Sherry La Porte

Geoffrey Christopherson

Fei Shen

Peter Chaikin

Brian Ellison

Raymond Brittingham

C Rex Reed

Lei Yin

Ann Lacombe

William Alan Mullen

Christopher John Rozell

Andrew Roden

Miguel Paganini

Gregory Wright

Mustafa Yazgan

Robb Fujioka

William Strohl

Ricardo Attar

Ijeoma Emeagwali

Paul James Edwards

Sean McGee

Alan Guihong Liu

Gary K Yeap

Francois Gaudet

Avinash Gill

Mark T Takamoto

Derrek Harrison

Gilbert Zaldivar

Heather Stephenson

Michael Luis Innocenzi

Christian Martinez

Trang V Luu

Yingzhe Li

Jonathan L Tronson

Michael D Hamling

Joseph T Hayes

Michael Ross

Yosub Shin

Timothy McCabe

Jeffry J Fedderly

Faiz Abbasi

Daniel Anthony Briere

Justin Nishiki

Paul H Kim

Qiang Chen

Eric Coates

Milata Mary Abraham

Jeffrey Wu

Douglas Quon Woo

Kenneth Randall

Stephanie Armstrong

Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.

Antigen binding regions against fibronectin type III domains and methods of using the same

In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a KL2B413 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include KL2B413.

Anti-idiotypic antibodies against anti-KLK2 antibodies

The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

Long acting amylin receptor agonists and uses thereof

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

GPRC5D chimeric antigen receptors and cells expressing the same

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof

In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.

Anti-idiotypic antibodies against anti-GPRC5D antibodies

The present disclosure provides bifunctional compounds of Formula (I), and pharmaceutically acceptable salts, isotopic forms, isolated stereoisomers, or mixtures of stereoisomers thereof, as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases

The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus ('T2DM'). Also, the compounds may be useful in the treatment of obesity.

GIPR-agonist compounds

Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.

Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent

A chip package system comprising N multiple processor cores can be tested by receiving a data file characterizing the chip package system. Thereafter, simulation testing is conducted for each core for each of Mstates using the data file such that each core is active in each state while all other cores are inactive. Each simulation test results in a simulation. The simulations are then combined to result in a composite test covering Mcombinations. Related apparatus, systems, techniques and articles are also described.

Integrated circuit composite test generation

An automated annotation system to automatically designate annotations to records within a report, which may perform operations that include: designating an annotation to a location, the annotation comprising a text string; identifying a record of the location within a report; selecting the annotation based on the record of the location within the report; and applying the text string of the annotation to the record within the report, according to certain example embodiments.

Automated annotation system for electronic logging devices

Systems and methods for targeted advertising to specific consumers are disclosed. A system may include a memory storing instructions; and at least one processor configured to execute the instructions to: receive, over a network, consumer data from a client device; identify a plurality of client-provided consumers from the consumer data; obtain a plurality of unique consumer identifiers corresponding to the plurality of client-provided consumers; and identify at least one first overlapping unique consumer identifier by matching at least one of the plurality of client-provided consumers with at least one publisher-provided consumer provided by a first publisher device of a plurality of publisher devices, the first publisher device having a highest priority among the plurality of publisher devices.

System and method for providing people-based audience planning

Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.

Methods of otoprotection against platinum-based antineoplastic agents

The present disclosure provides systems and methods for an address exchange system including a controller configured to provide an API configured to receive an identifier from a user and further configured not to receive a physical address from the user, wherein the user provides an item for shipment to the physical address. In response to receiving the identifier, the controller is further adapted to request the physical address from a data storage system wherein the data storage system stores an association between the identifier and the physical address and further stores one or more permission settings defining situations in which the physical address is to be provided in response to receipt of the identifier. In response to receipt of the identifier, the data storage system tests the permission settings to determine whether or not to provide the associated physical address.

Address exchange systems and methods

Growing community of inventors

Salt Lake City, UT, United States of America

John Lee